RUNX3 and osteosarcoma: Transcriptome sequencing combined with dual-luciferase assays identified RUNX3 as a direct target, and Western blot analyzed PI3K/Akt pathway activation.<h4>Results</h4>miR-495 was downregulated in osteosarcoma tissues/cells, positively correlating with patient survival.